Alzheimer’s Disease and Related Dementias

  • Gregg Warshaw
Chapter

Abstract

Cognitive impairment is common in the older adult and often represents an underlying, undetected clinical condition. When accompanied by other medical or social problems, cognitive impairment can precipitate stressful problems for and require decisions from families, caregivers, and clinicians. A thorough history is critical for successful diagnosis and treatment. Initially, the history should include a careful review, with both patient and family, of the chronologic course of the changes in mental status. The pace of the progression and the duration of the symptoms are particularly important. A patient with a history of deteriorating cognitive function over months or years presents a different diagnostic and treatment problem than one who presents with a mental status change over days or weeks (delirium). This chapter reviews the assessment of dementia and the current understanding of the etiology of Alzheimer’s disease (AD) and proposes management strategies for patients with dementias and their families.

Keywords

apoE4 Allele Lewy Body Dementia Progressive Dementia Relate Dementia Granulomatous Angiitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Folstein MF, Folstein SE, McHugh PR. “Mini mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98.PubMedCrossRefGoogle Scholar
  2. 2.
    McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group. Neurology 1984;34:939–44.PubMedCrossRefGoogle Scholar
  3. 3.
    NIH Consensus Conference. Differential diagnosis of dementing disease. JAMA 1987;2580:3411–16.Google Scholar
  4. 4.
    Larson EB, Reifler BV, Sami SM, et al. Diagnostic tests in the evaluation of dementia: a prospective study of 200 elderly outpatients. Arch Intern Med 1986;146:1917–22.PubMedCrossRefGoogle Scholar
  5. 5.
    Budinger TF. Future research in Alzheimer’s disease using imaging techniques. Neurobiol Aging 1994;15 Suppl:s41-s48.CrossRefGoogle Scholar
  6. 6.
    Evans DA. Estimated prevalence of Alzheimer’s disease in the United States. Milbank Q 1990;68:267–89.PubMedCrossRefGoogle Scholar
  7. 7.
    Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer’s disease in a community population. JAMA 1995;273:1354–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Price DL, Whitehouse PJ, Struble RG. Cellular pathology in Alzheimer’s and Parkinson’s diseases. Trends Neurosci 1986;9:29–33.CrossRefGoogle Scholar
  9. 9.
    Stern Y, Gurland B, Tatemichi TK, et al. Influence of education and occupation on the incidence of Alzheimer’s disease. JAMA 1994;271:1004–10.PubMedCrossRefGoogle Scholar
  10. 10.
    Breitner JCS. Clinical genetics and genetic counseling in Alzheimer’s disease. Ann Intern Med 1991;115:601–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Breitner JCS, Silverman JM, Mohs RC, Davis KL. Familial aggregation of Alzheimer’s disease. Neurology 1988;38:207.PubMedCrossRefGoogle Scholar
  12. 12.
    Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993; 43:1467–72.PubMedCrossRefGoogle Scholar
  13. 13.
    Peterson RC, Smith G, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. JAMA 1995;273: 1274–8.CrossRefGoogle Scholar
  14. 14.
    Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752–8.CrossRefGoogle Scholar
  15. 15.
    Statement on use of apolipoprotein E testing for Alzheimer Disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer’s disease. JAMA 1995;274:1627–9.CrossRefGoogle Scholar
  16. 16.
    Davies P. Biochemical changes in Alzheimer’s disease—senile dementia neurotransmitters in senile dementia of the Alzheimer’s type. In: Katzman R, editor. Congenital and acquired cognitive disorders. New York: Raven Press, 1979:153–60.Google Scholar
  17. 17.
    Davis KL, Mohs RC. Cholinergic drugs in Alzheimer’s disease. N Engl J Med 1986;315:1286.PubMedCrossRefGoogle Scholar
  18. 18.
    Davis KL, Thai LJ, Gamzu E, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzhiemer’s disease. N Engl J Med 1992;327:1253–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Lazarus LW, Newton N, Cohler B, et al. Frequency and presentation of depressive symptoms in patients with primary degenerative dementia. Am J Psychiatry 1987;144:41–5.PubMedGoogle Scholar
  20. 20.
    Holmes D, Ory M, Teresi J. Special dementia care: research, policy, and practice issues. Alzheimer Dis Assoc Disord 1994; 8 Suppl 1:55–513.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Gregg Warshaw

There are no affiliations available

Personalised recommendations